A Phase I, Randomized, Placebo-Controlled, Double-Blind Study Evaluating the Safety of Subcutaneous Single Dose Interleukin-7 in HIV-1-Infected Subjects Who Are Receiving Antiretroviral Treatment.

Trial Profile

A Phase I, Randomized, Placebo-Controlled, Double-Blind Study Evaluating the Safety of Subcutaneous Single Dose Interleukin-7 in HIV-1-Infected Subjects Who Are Receiving Antiretroviral Treatment.

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Jul 2013

At a glance

  • Drugs Interleukin-7 (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Acronyms PLEIADES
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 03 May 2012 Actual end date (1 Apr 2007) added as reported by ClinicalTrials.gov. (NCT00099671)
    • 03 May 2012 Actual end date (1 Apr 2007) added as reported by ClinicalTrials.gov. (NCT00099671)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top